SEC Form 4 · accession 0001209191-16-125839
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua A Kazam
Director
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 7:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2016 | A | 1,950 | $0.00 | A | 216,950 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $50.87 | Jun 1, 2016 | A | 7,000 | A | — | May 31, 2026 | Common Stock | 7,000 | 7,000 | D |
Explanation of responses
- F1The stock option shall vest in 24 successive equal monthly installments following the date of grant.